@article{355eb29e752f48b3b45480192baf58a3,
title = "Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma",
abstract = "Survival following a diagnosis of multiple myeloma (MM) varies between patients and some of these differences may be a consequence of inherited genetic variation. In this study, to identify genetic markers associated with MM overall survival (MM-OS), we conduct a meta-analysis of four patient series of European ancestry, totalling 3,256 patients with 1,200 MM-associated deaths. Each series is genotyped for ∼600,000 single nucleotide polymorphisms across the genome; genotypes for six million common variants are imputed using 1000 Genomes Project and UK10K as the reference. The association between genotype and OS is assessed by Cox proportional hazards model adjusting for age, sex, International staging system and treatment. We identify a locus at 6q25.1 marked by rs12374648 associated with MM-OS (hazard ratio=1.34, 95% confidence interval=1.22-1.48, P=4.69 × 10 -9). Our findings have potential clinical implications since they demonstrate that inherited genotypes can provide prognostic information in addition to conventional tumor acquired prognostic factors.",
author = "Johnson, {David C.} and Niels Weinhold and Mitchell, {Jonathan S.} and Bowang Chen and Martin Kaiser and Begum, {Dil B.} and Jens Hillengass and Uta Bertsch and Gregory, {Walter A.} and David Cairns and Jackson, {Graham H.} and Asta F{\"o}rsti and Jolanta Nickel and Per Hoffmann and N{\"o}ethen, {Markus M.} and Stephens, {Owen W.} and Bart Barlogie and Davis, {Faith E.} and Kari Hemminki and Hartmut Goldschmidt and Houlston, {Richard S.} and Morgan, {Gareth J.}",
note = "Funding Information: Myeloma UK provided principal funding for this study in the UK. Additional funding was provided by Leukaemia & Lymphoma Research, Cancer Research UK (C1298/A8362 supported by the Bobby Moore Fund) and the NHS via the Biological Research Centre of the National Institute for Health Research at the Royal Marsden Hospital NHS Trust. In Germany (Heidelberg) funding was provided by the Dietmar-Hopp-Stiftung Walldorf, the University Hospital Heidelberg, Deutsche Krebshilfe and the Systems Medicine funding of the German Ministry of Education and Science. In addition, the study is funded by the German Ministry of Education and Science and the German Research Council (DFG; Project SI 236/8-1, SI236/9-1, ER 155/6-1, and the DFG CRU 216). We are grateful to all the patients and investigators at the individual centres for their participation. The US study was supported by a grant from the National Institutes of Health (P01CA055819). We also thank the staff of the CTRU University of Leeds and the NCRI haematology Clinical Studies Group. Funding Information: Myeloma UK provided principal funding for this study in the UK. Additional funding was provided by Leukaemia & Lymphoma Research, Cancer Research UK (C1298/A8362 supported by the Bobby Moore Fund) and the NHS via the Biological Research Centre of the National Institute for Health Research at the Royal Marsden Hospital NHS Trust. In Germany (Heidelberg) funding was provided by the Dietmar-Hopp-Stiftung Walldorf, the University Hospital Heidelberg, Deutsche Krebshilfe and the Systems Medicine funding of the German Ministry of Education and Science. In addition, the study is funded by the German Ministry of Education and Science and the German Research Council (DFG; Project SI 236/8-1, SI236/9-1, ER 155/6-1, and the DFG CRU 216). We are grateful to all the patients and investigators at the individual centres for their participation. The US study was supported by a grant from the National Institutes of Health (P01CA055819). We also thank the staff of the CTRU University of Leeds and the NCRI haematology Clinical Studies Group.",
year = "2016",
month = jan,
day = "8",
doi = "10.1038/ncomms10290",
language = "English",
volume = "7",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Research",
}